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Over recent years tremendous progress has beenmade towards understanding themolecular and cellularmech-
anism bywhich estrogens exert enhancing effects on cognition, and how they act as a neuroprotective or neuro-
trophic agent in disease. Currently, much of this work has been carried out in animal models with only a limited
number of studies using native human tissue or cells. Recent advances in stem cell technology nowmake it pos-
sible to reprogramsomatic cells fromhumans into induced pluripotent stemcells (iPSCs), which can subsequent-
ly be differentiated into neurons of speciﬁc lineages. Importantly, the reprogramming of cells allows for the
generation of iPSCs that retain the genetic “makeup” of the donor. Therefore, it is possible to generate iPSC-
derived neurons from patients diagnosedwith speciﬁc diseases, that harbor the complex genetic background as-
sociatedwith the disorder. Here, we review the iPSC technology and how it's currently being used tomodel neu-
ral development and neurological diseases. Furthermore, we explore whether this cellular system could be used
to understand the role of estrogens in human neurons, and present preliminary data in support of this. We fur-
ther suggest that the use of iPSC technology offers a novel system to not only further understand estrogens' ef-
fects in human cells, but also to investigate the mechanism by which estrogens are beneﬁcial in disease.
Developing a greater understanding of these mechanisms in native human cells will also aid in the
development of safer and more effective estrogen-based therapeutics.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).IntroductionThere are multiple lines of evidence that estrogens exert a powerful
inﬂuence over cognition (Brinton, 2009; Daniel, 2013; Frick, 2012;
Galea et al., 2008; Luine, 2008, 2014). Studies using animal models
have demonstrated that estrogens, in particular 17β-estradiol, can in-
ﬂuence hippocampal and cortical brain regions to modulate cognitive
function, including learning and memory (Frick, 2009; Galea et al.,
2008; Luine, 2008). This is in addition to the effects 17β-estradiol has
on reproductive and sexual behaviours, regulated by its actions in the
hypothalamus (Micevych et al., 2009; Roepke et al., 2011). At the cellu-
lar levels, the effects on cognitive function are thought to be driven by
17β-estradiol's effects on synapse structure and function (Brinton,
2009; Srivastava et al., 2013). In addition to these neurotrophic effects,
multiple studies have also indicated that 17β-estradiol has potent
neuroprotective actions (Arevalo et al., 2015), and has been suggested
to be a possible therapeutic avenue for the treatment of severallinical Neuroscience, The James
, London SE5 8AF, UK.
astava).
c. This is an open access article underneurodevelopmental, psychiatric and neurodegenerative disorders
(Gillies and McArthur, 2010; Hughes et al., 2009; Srivastava and
Penzes, 2011).
To date, much of our understanding of the molecular and cellular
mechanisms that underlie the effect of estrogen have come from animal
based in vitro and in vivo models. Conversely, our understanding of the
mechanisms that underlie estrogens' effects in human neurons is limit-
ed. Indeed, it has not been possible to investigate the actions of estro-
gens at a molecular level in native human neurons, and thus to
validate whether or not the actions of estrogens as determined in ani-
mal models are comparable to its actions in human neurons. This is in
part due to the availability of, and the ethical considerations when
using human tissue. These issues result in the lack of a suitable and
reproducible cellular system that faithfully recapitulates a human neu-
ronal cellular environment and that allows detailed cellular and molec-
ular studies to be carried out. It is also important to recognise that while
animal studies support a beneﬁcial role for estrogens in a range of
neurodevelopmental, psychiatric and neurodegenerative disorders,
how these data translates to humans is unclear. This is particularly
important, when considering that there has not been much success in
translating preclinical work into novel therapeutic agents to treatthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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disorders. This lack of conversion is due to many factors, but are likely
to include species differences, differences in brain complexity and
disease-speciﬁc phenotypes (Dragunow, 2008). Another important fac-
tor to consider is the potential negative effects of estrogen, or estrogen-
based therapies such as increased risk of cardiovascular problems and
increased risk of developing cancers. An alternative approach would
be tomimic estrogenic-mediated positive effects bymodulating speciﬁc
ERs (Hughes et al., 2009; Zhao et al., 2005) and/or regulating 17β-
estradiol intracellular molecular targets. Such strategies could exploit
the beneﬁcial effects of estrogens without the harmful side effects.
Therefore, in order to utilize estrogens or estrogen-based therapeutic
for the treatment of neurodevelopmental or neurodegenerative disor-
ders, a greater understanding of the effects these compounds have on
native human cells and in a disease context is critical (Gillies and
McArthur, 2010; Hughes et al., 2009; Srivastava and Penzes, 2011).
Recent advances in stem cell biology are now providing us the tools
in which to study basic and disease mechanisms in native human
neurons (Brennand et al., 2012; Cocks et al., 2014; Dolmetsch and
Geschwind, 2011; Gaspard and Vanderhaeghen, 2011). This has led to
the ability to reprogram patient somatic cells into human induced
pluripotent stem cells (hiPSCs) and the subsequent differentiation
into neurons of speciﬁc lineages (Dolmetsch and Geschwind, 2011;
Gaspard and Vanderhaeghen, 2011). Importantly, these cells encapsu-
late and recapitulate the genetic landscape and cellular abnormalities
associated with complex disease (Durak and Tsai, 2014; Yu et al.,
2013). Critically, this approach provides a potentially limitless source
of live human cells for understanding basic neurobiology and disease
pathophysiology, and formodelling the actions of potential drug targets
(Brennand et al., 2012; Cocks et al., 2014; Dolmetsch and Geschwind,
2011; Gaspard and Vanderhaeghen, 2011). In this review, we will
review a) the evidence that estrogens inﬂuence human cognition and
maybe beneﬁcial in the treatment of neurodevelopment/psychiatric
disorders; b) recent advances in our ability to generate hiPSCs and
their use in elucidating both basic and disease relevant mechanisms;
c) the current limitations and efforts to overcome them when using
iPSCs; and d) present some preliminary data demonstrating that
neurons differentiated from hiPSCs are responsive to 17β-estradiol
treatment.
How do estrogens inﬂuence cognition?
During early brain development 17β-estradiol has many roles,
ranging from the control of cell proliferation and apoptosis to synapto-
genesis and neurogenesis (McCarthy, 2008; Sakuma, 2009). In addition,
17β-estradiol is a critical factor in determining sexual differentiation
during development. It has an organisational role which contributes to
the establishment of sex differences by inﬂuencing the sexually dimor-
phic formation of the neural circuitry that encodes reproductive and
socio-aggressive behaviours (H. Lee et al., 2014; Ubuka and Tsutsui,
2014; Unger et al., 2015; Yang and Shah, 2014). Accumulating evidence
indicates that 17β-estradiol's ability to regulate synapse structure and
function, and thus neural circuitry, underlies its inﬂuence over cognitive
function (Luine and Frankfurt, 2012; Sellers et al., 2014; Srivastava et al.,
2013). In the cortex and hippocampus, 17β-estradiol has been shown to
modulate dendritic spine and synapse formation and density (Luine and
Frankfurt, 2012; Srivastava et al., 2013), long-term potentiation (LTP)
(Foy et al., 1999; Kramar et al., 2009; Xiao et al., 2012) and long-term
depression (LTD) (Mukai et al., 2007). Indeed, regulation of these
cellular parameters are thought to be key events and cellular correlates
of memory and learning (Fu and Zuo, 2011; Holtmaat and Svoboda,
2009; Malenka and Bear, 2004; Morris, 2003).
The actions of 17β-estradiol are mediated by the classic estrogen
receptors (ERs) ERα, ERβ, as well as the G-protein coupled receptor,
GPER1 (Brinton, 2009; Sellers et al., 2014; Srivastava and Evans,
2013). These receptors mediate both rapid, membrane-initiatedsignalling and longer-term/chronic actions via the regulation of gene
transcription (Brinton, 2009; McCarthy, 2008; Srivastava et al., 2013).
Both ERα and ERβ dimerize in response to 17β-estradiol binding, and
subsequently translocate to the nucleus, where they can bind and inﬂu-
ence the expression of certain genes (Greene et al., 1986). However,
there is a growing appreciation that 17β-estradiol can act via ERα,
ERβ and GPER1 to rapidly regulate non-classical signalling resulting in
a modulation of cellular physiology (Spencer et al., 2008; Srivastava
et al., 2013; Woolley, 2007). Activation of these non-classical pathways
by 17β-estradiol can result in multiple cellular effects, including imme-
diate effects on cell physiology and even on protein synthesis or gene
transcription (Sellers et al., 2014). Importantly, signalling via speciﬁc
ERs and the activation of these pathways have also been shown to be
required for 17β-estradiol-mediated enhancements of cognitive func-
tion (Ervin et al., 2013; Frick, 2012; Gabor et al., 2015; Hawley et al.,
2014; Luine and Frankfurt, 2012; Srivastava et al., 2013). It is also impor-
tant to note that the precise establishment of neural circuitry during
development, as well as the proper regulation and maintenance of
synaptic connectivity throughout the lifetime of an animal, is essen-
tial for normal brain/cognitive function. Indeed disruptions in these
process are thought to be a major contributing factor to a number of
neurodevelopmental and neurodegenerative disorders (Penzes et al.,
2011; Tau and Peterson, 2010; van Spronsen and Hoogenraad, 2010).
As such, the ability of 17β-estradiol to regulate synapse structure and
function may contribute to its beneﬁcial effects in disease (Srivastava
and Penzes, 2011; Srivastava et al., 2013).
While the effects of estrogens on cognition have beenwell established
in animal models, the reported effects of estrogens on cognitive function
in human have been much more varied (Luine, 2014; Sherwin, 2012).
Nevertheless, multiple studies in human females have reported that
administration of estrogens have a positive effect on cognitive function,
including memory (Duff and Hampson, 2000; Hampson and Morley,
2013; Hogervorst and Bandelow, 2010; Sherwin, 2012; Smith et al.,
2006). In addition, several studies have suggested that 17β-estradiol
levels correlate with cognitive performance. For example, during the
midluteal phase when 17β-estradiol levels are at their relative height,
women have been shown to have a transient increase in performance
in typically female-favouringmeasures of cognition such as verbal ﬂuen-
cy. This is opposed to the menstrual phase in these same women, during
which 17β-estradiol decline correlates with a transient increase in
performance in typically male-favouring measures of cognition such as
spatial ability (Hampson, 1990). This relationship between estrogen con-
centration and cognition has since been reiterated by several studies
(Hampson and Morley, 2013; Hogervorst et al., 2004; Phillips and
Sherwin, 1992b). In addition, the loss of estrogens (and other steroids)
following menopause has been suggested to dramatically increase a
woman's risk of memory loss (Maki and Henderson, 2012; Ryan et al.,
2012). Interestingly, it has also been shown that this decline can be atten-
uated by administering exogenous estrogens relatively early in meno-
pause (Phillips and Sherwin, 1992a; Sherwin, 1988). However not all
studies have reportedpositive effects on cognition,with studies reporting
no or even negative effects (Daniel, 2013; Hogervorst and Bandelow,
2010; Luine, 2014; Sherwin, 2012). As discussed by Luine (2014) in the
primer for this special issue, the variation seen in human studies could
be due to difﬁculties in experimental design or potential environmental
cofounders. However, another possibility is that estrogens do not affect
human cognition in the same manner as that seen in animal models,
due to differences in the basic underlying molecular and cellular
mechanisms.
Estrogens and disease: therapeutic potential?
There is also substantial evidence that estrogens exert neuroprotec-
tive effects andmay also have beneﬁcial effects in animal models of dis-
ease (Arevalo et al., 2015; Frick, 2012; Gillies and McArthur, 2010).
Preclinical studies have provided evidence that estrogen, or estrogen-
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treatment of neurodevelopmental and neurodegenerative disorders
such as schizophrenia (Gogos and van den Buuse, 2015; Labouesse
et al., 2015), depression (Bredemann and McMahon, 2014; Hajszan
et al., 2010; Walf et al., 2008), Parkinson's disease (Bourque et al.,
2012; Rodriguez-Perez et al., 2013) and Alzheimer's disease (Logan
et al., 2011; Zhang et al., 2012; Zhao et al., 2013). It has also been hy-
pothesized that the beneﬁcial effects of 17β-estradiol in these disorders
are mediated, in part, through themodulation of neural circuitry (Frick,
2012; Gillies and McArthur, 2010; Hughes et al., 2009; Srivastava and
Penzes, 2011). For example, the antidepressive effect of 17β-estradiol
in a learned helplessness model of depression occurs concurrently
with an increase in spinogenesis and LTP in CA1 neurons (Bredemann
and McMahon, 2014; Hajszan et al., 2010). Furthermore, selective
activation of ERβ has anti-depressive-like effects in a number of cogni-
tive tests (Walf et al., 2008); this is in addition to ERβ-mediated modu-
lation of synapse structure and function (Kramar et al., 2009; Srivastava
et al., 2010). Interestingly, Logan et al. (2011), demonstrated that 17β-
estradiol was sufﬁcient to rescue deﬁcits in dendritic spine density
induced by soluble beta amyloid (Aβ) oligomers in neuronal cultures.
Moreover, the authors reported that administration of 17β-estradiol
prevented Aβ oligomer-induced impairment of inhibitory avoidance
tasks (Logan et al., 2011), indicating that 17β-estradiol's regulation of
synapse structure contributes to its beneﬁcial effects on Aβ-induced
cognitive deﬁcits.
Several clinical studies and meta-analyses have been carried out
investigating the potential beneﬁcial roles of 17β-estradiol or selective
estrogen receptor modulators (SERMs) in a range of disorders including
schizophrenia (Kindler et al., 2015; Kulkarni et al., 2015; Torrey and
Davis, 2012; Weickert et al., 2015), major depression (Kornstein et al.,
2010; Young et al., 2007), and even Alzheimer's disease (Maki, 2013;
Wharton et al., 2011). For example, in a recent large-scale, randomized-
control study, Kulkarni et al. (2015) reported that administration of
17β-estradiol to treatment-resistant female schizophrenic patients, re-
sulted in a clinically relevant amelioration of schizophrenic symptoms.
In this study, 200 μg of 17β-estradiol was delivered via a transdermal
patch to female patients for 8 weeks; patients receiving this treatment
showed a greater decrease in the positive and negative syndrome scale
(PANSS) than 100 μg 17β-estradiol or placebo. Several recent studies
have also investigated the therapeutic potential of the SERM raloxifene
in schizophrenia. In a 12 week double-blind, placebo-controlled study,
orally administered raloxifene improved probabilistic association learn-
ing and signiﬁcantly increased fMRI blood oxygen level-dependent
(BOLD) activity in the hippocampus and parahippocampal gyrus relative
to placebo, in male and female schizophrenic patients (Kindler et al.,
2015). In a subsequent study by the same group, raloxifene, administered
orally, improved memory and attention/processing speeds in male and
female schizophrenic patients, compared to placebo (Weickert et al.,
2015).
While these studies do support a positive role for estrogens, or
estrogen-based therapies (Craig and Murphy, 2010; Cyr et al., 2000;
Frick, 2009; Gillies and McArthur, 2010; Kulkarni et al., 2008; J.H. Lee
et al., 2014; Maki and Henderson, 2012; Sherwin, 2009; Torrey and
Davis, 2012), they do not support estrogens as a long-term treatment.
Previous studies from theWomen'sHealth Initiative (WHI) investigated
the potential of Hormone Replacement Therapy (HRT) as a therapeutic
avenue for the treatment of ageing and dementia. The ﬁndings of the
WHI studies reported a decrease in cognitive function and an increased
risk of dementia and stroke inwomenover 65 years of agewho received
conjugated equine estrogens (CEE) plus medroxyprogesterone acetate
(MPA) compared to those who received placebo (Espeland et al.,
2004; Rossouw et al., 2002; Shumaker et al., 2004). However, these
studies were carried out in females that were postmenopasual for
~15–20 years, and the HRT studies used horse derived estrogens,
made upmostly of estrone, an estrogen that has varied and often oppos-
ing effects to 17β-estradiol, and progesterone on cognition in animalmodels (Barha et al., 2010; Barha and Galea, 2013; Engler-Chiurazzi
et al., 2012; McClure et al., 2013). Moreover, a direct comparison of
CEE and 17β-estradiol on verbal memory performance in postmeno-
pausal women indicates that 17β-estradiol has a more potent effect
on memory than CEE (Wroolie et al., 2011). It is also thought that the
physiological status of women is critical in determining the effective-
ness of estrogen on cognition and it has been hypothesized that post-
menopausal women lose their responsiveness to estrogens about
5 years after menopause (Asthana et al., 2009; Craig et al., 2005;
Hogervorst and Bandelow, 2010; Maki, 2013; Maki and Henderson,
2012; Singh et al., 2013). Indeed, basic studies have also hypothesized
that there is a critical period, or “window of opportunity” following
menopause or surgical removal of ovaries, when the brain is still
responsive to estrogens and the hormone can exert positive effects
(Singh et al., 2013; Vedder et al., 2014). Conversely, treatment with
estrogens after this time may exert negative, or adverse, effects on
cognition (Asthana et al., 2009; Maki, 2013; Sherwin, 2009).
As discussed above, our understanding of the potential beneﬁcial
effects of estrogens, or in developing novel estrogen-based therapies,
is limited due to the inability to perform in depth molecular studies of
estrogens in human neurons that faithfully recapitulate the genetic,
and therefore the cellular environment of speciﬁc diseases. Understand-
ing such mechanisms would not only enhance our understandings of
estrogen function in humans, but would enable us to develop safer
and more effective estrogen-based therapies. Other alternatives, such
as human post-mortem brain tissue and genetically-modiﬁed model
organisms have provided insights into how estrogens are beneﬁcial in
a number of disorders, but these approaches have limitations. Post-
mortem tissue is not living tissue and does not allow researchers to
investigate the progression of the disorder. A limitation of animal
models is that they often do not faithfully reﬂect human pathophysiol-
ogy. Moreover, many disorders of the brain have a complex genetic
underpinning, and thus it is not currently possible to fully recapitulate
the complex genetic landscape in traditional animal models. Therefore,
the ability to determine the potential effectiveness of therapeutic
agents, such as estrogens, or to identify and test novel estrogen-based
compounds/therapies is currently limited. If we are to fully recognise
the potential of estrogen-based therapies, whether it be for females or
for males, it is critical to investigate them in a cellular model which
encapsulates the complex nature of these diseases, and within a native
human cellular environment.
Generation and differentiation of hiPSCs
iPSC reprogramming technology
The method of reprogramming adult somatic cells to pluripotent
stem cells was ﬁrst described in 2006 by Takahashi and Yamanaka.
They reported that dermal ﬁbroblasts from adult mice could be
reprogrammed into a pluripotent state by retroviral transduction of
four transcription factors: OCT4, KLF4, c-MYC and SOX2 (Takahashi and
Yamanaka, 2006). The reprogrammed cells were termed induced
pluripotent stem cells (iPSCs), and are similar to embryonic stem cells
(ESCs) in theirmorphology, proliferation, surface antigens, gene expres-
sion and capacity to differentiate into the cell types of the three primor-
dial germ layers. A year later, Takahashi et al. (Takahashi et al., 2007b)
applied the same technology to human adult dermal ﬁbroblasts to
generate the ﬁrst human iPSCs (hiPSCs). Yamanaka's seminal studies
provided an avenue to generate patient and disease-speciﬁc iPSCs and
led to his being awarded the Nobel Prize in Medicine and Physiology
in 2012. This discovery, combinedwith protocols for the directed differ-
entiation of neurons, enabled access to these cell types without the
ethical issues involved with the use of human embryonic stem cells.
Since this discovery, many others have shown that it is possible to
generate hiPSCs from other adult somatic cell types, including peripher-
al blood (Loh et al., 2009), hair follicles (Aasen et al., 2008), amniotic
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2012) and various other cell types (Aoki et al., 2010; Bar-Nur et al.,
2011; Eminli et al., 2009; Giorgetti et al., 2009; Haase et al., 2009; J.B.
Kim et al., 2009; Liu et al., 2010; Nakagawa et al., 2008; Sugii et al.,
2011; Yu et al., 2007). Although a well-established cell type in many
ﬁelds of research, due to their ease of handling and the cost-
effectiveness, there are disadvantages to the use of ﬁbroblasts as a
starting cell type for producing hiPSCs. Patient dermal ﬁbroblasts
are obtained from painful skin punch biopsies that present risk of
infections and allergic reactions to anaesthetics, andmust be performed
by trained professionals. In addition, ﬁbroblasts are reprogrammed
with a longer time frame and less efﬁciency than other somatic cell
types (Aasen et al., 2008). Thus, these studies have advanced hiPSC re-
search by enabling non-invasive methods of acquiring starting material
and reducing the time and costs, while increasing the efﬁciency of
reprogramming.
Conventional hiPSC reprogramming has made use of integrating
viral vectors, such as retroviral and lentiviral vectors, for the delivery
of the four pluripotency factors (OCT4, KLF4, c-MYC and SOX2) into the
starting cell types (Takahashi et al., 2007b; Yu et al., 2007). Integrating
viral vectors were critical in the development of iPSC technology due
to its ability to enable long-term transgene expression, but result in
the integration of viral DNA into thehost genome. This type of transgene
delivery has disadvantages, such as the risk of insertional mutagenesis,
residual expression of integrated transgenes, and uncontrolled activa-
tion or inactivation of the integrated transgenes, which is critical in
the case of iPSC reprogramming, since all four of the pluripotency
factors are oncogenic (Hu, 2014). Tremendous effort has since led to
the development of alternative protocols to avoid the integration of
the pluripotency factors into the host genome. It is now possible to
generate hiPSCs with the use of episomal vectors (Sendai vectors;
(Fusaki et al., 2009)), non-integrating viral vectors (Sarkis et al.,
2008), small molecules (Ichida, 2009; Lyssiotis et al., 2009; Shi et al.,
2008), protein transduction (D. Kim et al., 2009) and microRNAs (Pfaff
et al., 2011; Subramanyam et al., 2011) (Fig. 1). These methods have
addressed many of the issues associated with integrating viral vectors
and advanced hiPSC research by producing hiPSC lines with increased
efﬁciency, low toxicity and free of transgene footprints, making them
feasible for clinical studies such as cell replacement therapies. The
efﬁciency of hiPSC generation has greatly improved since TakahashiHuman
cells
Human induced 
pluripotent stem 
cells (hiPSCs)
Somatic cells
‘Yamanaka’ 
factors: OCT4, 
KLF4, c-MYC, 
SOX2
e.g. skin 
fibroblasts or hair 
keratinocytes
Fig. 1. Promise of hiPSCs. Schematic representation of how somatic cells taken from a patien
factors, OCT4, KLF4, c-MYC and SOX2. Subsequent differentiation of human iPSCs (hiPSCs) into n
ﬁcation of potential drug targets. In addition, hiPSC derived neurons may function as a cellularand Yamanaka's initial breakthrough, and the technology continues to
develop.
Neuronal differentiation of hiPSCs
A key component of using hiPSCs to elucidate basic and disease
relevant mechanisms is the ability to direct the differentiation of stem
cells to speciﬁc neuronal cell types. The pathways involved in neural de-
velopment were ﬁrst elucidated from studies of animal embryology.
The ﬁrst step in the development of the neural tube, neural induction,
is believed to be the default pathway, involving the bonemorphogenet-
ic proteins (BMPs), Wnt and ﬁbroblast growth factor (FGF) signalling
pathways (Aubert et al., 2002; Chambers et al., 2009; LaVaute et al.,
2009). Neural induction leads to a default and primitive anterior identi-
ty, which is subsequently patterned by extrinsic morphogens such
as Wnts, FGFs, retinoic acid and Sonic Hedgehog (Shh), to give rise
forebrain, midbrain, hindbrain or spinal cord domains.
Neuronal differentiation of hiPSCs follow the same pathways as
in vivo to give rise to mature neuronal populations (Shi et al., 2012)
(Fig. 2). The most efﬁcient neural induction of hiPSCs is achieved by
dual inhibition of the SMAD signalling pathway (Chambers et al.,
2009). This involves the synergistic inhibition of the BMP and TGFβ
pathways to achieve rapid and uniformneural conversion of pluripotent
cells. Using small molecule antagonists or endogenous inhibitors, it is
possible to induce neural conversion to give rise to a population of
neural progenitors (Boissart et al., 2013; Chambers et al., 2009; Shi
et al., 2012). Neural progenitors may then be patterned into neuronal
cell types with regional identities using speciﬁc combinations of
morphogens, small molecules, growth factors and transcription factors.
Depending on the combination and timing of these signals, a variety of
neuronal cell types can be obtained, including telecephalic precursors
(Watanabe et al., 2005), midbrain dopaminergic neurons (Kawasaki
et al., 2000), basal forebrain cholinergic neurons (Bissonnette et al.,
2011), spinal motor neurons (Hu and Zhang, 2009), as well as glial
cells, such as astrocytes (Serio et al., 2013) and oligodendrocytes
(Hu et al., 2009).
It should be noted that protocols for the directed differentiation of
hiPSCs into neuronal subtypes are imperfect, often yielding a heteroge-
neous population of cell types. For instance, derivation of basal forebrain
cholinergic neurons from human pluripotent stem cells yields both cellsDisease 
pathophysiology
Human
Neurons
Identifying novel
drug targets
Drug
Screening
t can be reprogrammed into induced pluripotent stem cells (iPSCs) using the ‘Yamanaka’
eurons of deﬁne lineage allow for investigations into disease pathophysiology and identi-
platform in which drug screens can be carried out using disease relevant neurons.
hiPSCs
Inner cell mass
D0
Blastocyst
Neural
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Neural rosettes
6 Neural groove
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Fig. 2. Schematic representation of in vitro neural differentiation and human neural development. Schematic representation of the mechanisms of in vitro neural differentiation of
hiPSCs and in vivoneural induction and early patterning of theneural plate/tube. hiPSCsneural induction and neural progenitor speciﬁcation followprocesses as in vivo to give rise towell-
deﬁned neuronal populations. Before neural induction, hiPSCs correspond to pluripotent cells within the inner cell mass of the blastocyst. Neural induction, regulated by bone morpho-
genetic proteins (BMP),Wnt and ﬁbroblast growth factors, gives rise to neuroprogenitor cells (NPCs), and the formation of neural rosette structures, which recapitulates a default anterior
identity. Subsequent patterning by addition of extrinsic morphogens including Wnts, FGFs, retinoic acid and Sonic Hedgehog, give rise to forebrain, midbrain, hindbrain or spinal cord
progenitors and subsequently post-mitotic neurons. Scale bar = 10 μm.
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neurons and other cell types (Bissonnette et al., 2011). In addition,
each protocol differs in the efﬁciency of directed differentiation,
with some protocols generating highly pure neuronal subtypes (Du
et al., 2015), and others achieving lower yields (Kiskinis et al.,
2014). Furthermore, many protocols are focused on the directed dif-
ferentiation of one particular neuronal subtype, neglecting the role
of neighbouring cell types, such as glia, that are present in the
in vivo environment. In fact, astroglia has been shown to have acritical role in the functional maturation of hiPSC-derived neurons
(Tang et al., 2013). Despite these caveats, the last decade of research
has seen a vast improvement in neuronal differentiation of human
pluripotent stem cells. These efforts have identiﬁed novel small mol-
ecules that enhance neuronal differentiation and reduce costs, re-
ducing the amount of time required to yield highly enriched
populations of speciﬁc neuronal subtypes (Kim et al., 2010). In addi-
tion, they provide important guidelines and benchmarks for future
hiPSC studies of basic neurobiology and disease modelling.
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Several studies have recently demonstrated the utility of hiPSCs for
functional studies of human neural development. Shi et al. (2012)
showed that the distinct steps of human cortical development can be re-
capitulated in a hiPSC system, from cortical induction to the formation
of functional excitatory synapses (Fig. 3). This system closely mirrored
the in vivo cortex, in terms of the temporal order of development,
speciﬁcity of circuit formation, and laminar organisation of projection
neurons (Shi et al., 2012). Importantly, this system enabled the genera-
tion of all classes of cortical projection neurons for the ﬁrst time, includ-
ing the formation of superﬁcial layer neurons, which are absent in
mouse cortical development. Similarly, Espuny-Camacho et al. (2013)
reported that human corticogenesis can be recapitulated in hiPSCs in
the absence of extrinsicmorphogens, enabling the generation of diverse
pyramidal neuronswith distinct patterns of axonal projections and den-
dritic outgrowths that integrated functionally when grafted in neonatal
mouse brain (Espuny-Camacho et al., 2013). These studies show that
hESCs and hiPSCs both demonstrate a similar capacity to differentiate
into all classes of cortical projection neurons.
GABA interneurons are another major neuronal subtype of the
human cortex. Unlike cortical projection neurons, GABA interneurons
mainly originate from the medial ganglionic eminence and migrate to
the cortex during development (Sussel et al., 1999). Liu et al. (2013a,
b) used hiPSCs to examine the development of GABA interneurons.
This study showed that the differentiation of GABA interneurons from
hiPSCs follows the timeline of human GABA interneuron development,
from patterning of primitive neurepithelia to the generation of func-
tional neurons with inhibitory and excitatory inputs (Liu et al., 2013a).
Furthermore, multiple GABA interneuron subtypes were observed
in this chemically deﬁned system, with speciﬁc GABA populations
appearing according to their developmental schedule (Liu et al.,
2013a). In a related study, this group reported the use of this method
to successfully direct the differentiation of hESCs to medial ganglionic
eminence progenitors and subsequently, GABA interneurons (Liu
et al., 2013b). Interestingly, the transplantation of hESC-derived medial
ganglionic eminence progenitors to the hippocampi of mice led to
behavioural changes in learning and memory (Liu et al., 2013b). These
ﬁndings show that in addition to the study of basic neurobiology, hiPSCsN2:B27 + SMADi N2:B27 ONLYiPSC
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Similarly, others have investigated the development of other neuro-
nal cell types, including cerebellar Purkinje cells (Wang et al., 2015),
retinal cells (Meyer et al., 2009) and motor neurons (Toma et al.,
2015). More recently, hiPSC-derived neurons have been used to study
speciﬁc aspects of cell biology, such as mitochondrial biogenesis
(O'Brien et al., 2015) and neuromuscular junction development
(Yoshida et al., 2015). These studies show that hiPSC-derived neuronal
cell types possess many of cellular and physiological characteristics as
hESC-derived and endogenous neuronal cell types. Furthermore, hiPSCs
have beenused to generate a three-dimensionalmodel of humanneural
tissue. Lancaster et al. (2013) reported the development of brain tissue
fromhiPSCs, termed cerebral organoids. Cerebral organoids consisted of
discrete regions similar to the cerebral cortex, ventricles and retina tis-
sue, and recapitulated some key aspects of human cortical development
mentioned above (Lancaster et al., 2013). Similarly, Meyer et al. (2011)
showed that hiPSCs can be differentiated into 3D retinal structures
consisting of multiple retinal cell types, in a time frame similar to
normal human retinal development (Meyer et al., 2011). These studies
provide models to engineer human cortical circuits and investigate
cortical function that had not previously been possible with animal
models due to species differences.
Using iPSCs to model and investigate disease
One of the biggest challenges in the study of diseases of the nervous
system has been the inaccessibility of live human neural tissue from
patients. hiPSC technology combinedwithmethods of directed differen-
tiation provides a general solution to this impediment. An obvious
advantage of patient-speciﬁc hiPSCs is that they carry the same genetic
background as the patient, capturing the mutated genes, as well as the
known and unknown genetic modiﬁers that play important roles in
pathogenesis. In addition, patient-speciﬁc hiPSCs represent a more
physiologically relevant model system, negating the need to overex-
press proteins at superphysiological levels in current cellular and animal
models. Thus far, a number of groups have published studies of hiPSC
neurons from patients with various neurological conditions, including
neuropsychiatric disorders schizophrenia (SCZ) (Brennand et al.,B27 + DAPT B27 ONLY
20 *D23 D25
+ DAPT
D30
+ B27 ONLY
ITOR TERMINAL 
DIFFERENTIATION
D
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from keratinocytes of healthy individuals were neuralized as amonolayer in the presence
cells was formed, as determined by positive staining for nestin and SOX2. (C) Subsequent
his stage recapitulates neural tube formation with a clear central pseudo-lumen between
itive cells forming a radial structure surrounding the lumen. (D) Terminal differentiation
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Shcheglovitov et al., 2013), as well as neurodegenerative disorders
Alzheimer's disease (AD) (Israel et al., 2012), Parkinson's disease (PD)
(Devine et al., 2011) and amyotrophic lateral sclerosis (ALS) (Dimos
et al., 2008).
Several groups have reported the generation of hiPSCs from patients
with Rett syndrome, an ASD caused by mutations of the MECP2 gene.
Patient-speciﬁc hiPSCs maintained the parental mutation and were
pluripotent and able to differentiate into the three germ layers
(Ananiev et al., 2011; Cheung et al., 2011; Marchetto et al., 2010). All
three studies showed that neurons from Rett syndrome hiPSC-derived
neurons recapitulated a hallmark feature of ASD, reduction in soma
size. In addition, Marchetto et al. (2010) reported that Rett syndrome
hiPSC-derived neurons had fewer synapses, reduced spine density and
alterations in calcium signalling and defects in electrophysiology.
Altered dendritic arborisation and synaptic density are characteris-
tics that appear to be shared between ASD and SCZ. The generation of
hiPSCs from patients with SCZ has also been reported by independent
groups. Chiang et al. (Chiang et al., 2011) were the ﬁrst to generate
patient-speciﬁc hiPSCs from a patient with mutations in the DISC1
gene, albeit without reporting any SCZ-relevant phenotypes. Soon
after, Brennand et al. (2011) reported the generation of hiPSCs from
patients with childhood-onset SCZ or from families affected with
psychiatric disease, likely reﬂecting a genetic component to disease.
Patient-speciﬁc hiPSCs were indistinguishable from control hiPSCs in
pluripotency and in their ability to differentiate into functional neurons.
However, patient-speciﬁc hiPSC-derived neurons displayed decreased
neuronal connectivity, reduced neurite outgrowth and decreased
PSD95 protein levels, despite normal spontaneous neuronal activity
(Brennand et al., 2011). Interestingly, amore recent study onhiPSCs gen-
erated from patients with a family history of SCZ reported a discrepancy
in these observations. Robicsek et al. (2013) reported that patient-
speciﬁc hiPSC-derived neural progenitor cells (NPCs) exhibited abnormal
morphology and a delay in differentiation into dopaminergic neurons
and an inability to differentiate into glutamatergic neurons (Robicsek
et al., 2013). hiPSCs have also been generated from 22q13 deletion syn-
drome patients (Phelan-McDermid syndrome), who display intellectual
disability and an increase risk of ASDs. Amongst the gene deleted in this
region, SHANK3, which encodes a post-synaptic scaffold protein, has
also been associated with ASD, intellectual disability and SCZ. Neurons
derived from these patient-speciﬁc hiPSCs demonstrated reduced levels
of Shank3 expression and displayed deﬁcits in excitatory transmission
and synaptic number (Shcheglovitov et al., 2013). Remarkably, the
authors further demonstrated that overexpression of Shank3 or treat-
ment with IGF1 was sufﬁcient to restore synaptic deﬁcits in these
patient-speciﬁc hiPSC-derived neurons (Shcheglovitov et al., 2013). Col-
lectively, these studies have provided proof of concept by demonstrating
that cells derived from patient-speciﬁc hiPSC are a cellular system in
which to conﬁrm and elucidate the impact of genetic variations associat-
edwith complex disorder on cellular phenotypes. However,more recent-
ly, several studies have now used patient-speciﬁc hiPSCs as a tool to
investigate novel mechanisms and cellular phenotypes that may contrib-
ute to the pathophysiology of neurodevelopmental disorders. For exam-
ple, Wen et al. (2014) generated hiPSCs from 4 family members 2 of
which had a frameshift mutation in the DISC1 gene and were diagnosed
with SCZ or major depression, and 2 unaffected family members with
the mutation. Neurons generated from hiPSC of the affected family
members displayed reduced levels of the DISC1 protein, abnormal synap-
tic transmission and reduced synapse number, consistent with previous
reports using animal models (Hayashi-Takagi et al., 2010; Wen et al.,
2014). However, the authors further discovered that reduction in DISC1
expression also resulted in the dysregulation of multiple genes related
to synaptic and psychiatric disorder, hence uncovering a novel transcrip-
tional regulatory action for the DISC1 protein (Wen et al., 2014). Around
the same time, Yoon et al. (2014) generated hiPSCs from SCZ patients
with a 15q11.2 microdeletion; one of the genes expressed in this regionis CYFIP1, which has been associated with SCZ and ASDs. Using NPCs
derived from these patient-speciﬁc hiPSCs, the authors identiﬁed that
haploinsufﬁciency ofCFYIP1 resulted in a disruption in adherent junctions
and apical polarity, an effect that they further demonstrated to disrupt
radial glial cell localization in a mouse model (Yoon et al., 2014). This
study further demonstrates how hiPSCs can be an entry point to discov-
ering novel insights into disease pathology (Durak and Tsai, 2014).
In addition to these studies, hiPSCs have also been used to success-
fully model aspects of late-onset neurodegenerative disorders.
Shortly after the generation of the ﬁrst hiPSCs, Dimos et al. (2008)
were the ﬁrst to report the generation of patient-speciﬁc hiPSCs from
an 82-year-old woman with ALS, and their differentiation into motor
neurons. Although this study did not report any disease phenotypes, a
number of studies have since shown that patient-derived hiPSCs do re-
capitulate disease-relevant phenotypes upon neuronal differentiation.
After the initial proof-of-principle study demonstrating the feasibility
of generating patient-speciﬁc hiPSCs and their differentiation into
motor neurons, several groups reported the generation of hiPSCs from
ALS patients with known and well characterised pathogenic mutations.
These studies have shown that neurons and glia derived from patient-
speciﬁc hiPSCs recapitulate key pathological phenotypes of ALS, includ-
ing mutant cellular and biochemical features, and cellular vulnerability
(Almeida et al., 2013; Bilican et al., 2012; Egawa et al., 2012; Sareen
et al., 2013). A comprehensive study of hiPSCs generated from patients
with familial AD and sporadic AD reported key features of AD, such as
higher levels of amyloid-beta and phosphorylated tau, in both familial
and sporadic AD hiPSC-derived neurons (Israel et al., 2012). Similarly,
midbrain dopaminergic neurons from hiPSCs generated from a familial
PD patientwith amutation in the gene encoding alpha-synuclein exhib-
it increased levels of alpha-synuclein protein, recapitulating the cause of
PD (Devine et al., 2011). Other PD-relevant phenotypes have also been
observed in hiPSC-derived neurons from PD patients with mutations
in the PINK1 and LRRK2 genes, including increased production of
mitochondrial reactive oxygen species and abnormal mitochondrial
transport (Cooper et al., 2012).
Several recent studies have also combined genome editing tools
with hiPSCs to both model the cellular phenotypes associated with
ALS, themost common adult-onset motor neuron disease, and to inves-
tigate the genetic contribution to disease pathogenesis. Two indepen-
dent groups reported the generation of hiPSCs from ALS patients with
mutations in the SOD1 gene (Chen et al., 2014; Kiskinis et al., 2014).
Kiskinis et al. (2014) reported that patient-speciﬁc hiPSC-derived
motor neurons exhibited increased cell death and reduced soma size
and shorter neurites, whereas Chen et al. (2014) observed aggregation
of mutant SOD1 protein and neuroﬁlament inclusions in patient-
speciﬁc hiPSC-derived motor neurons (Chen et al., 2014; Kiskinis et al.,
2014). Kiskinis et al. (2014) and Chen et al. (2014) used zinc-ﬁnger
nuclease and TALENs, respectively, to target the correction of the SOD1
mutation in the patient-speciﬁc hiPSCs. Both studies showed that genetic
correction of the SOD1mutation rescued the ALS-associated phenotypes.
These studies provide support for the use of hiPSCs formodelling the
molecular pathogenesis of diseases of the nervous system. In addition to
diseasemodelling, patient-speciﬁc iPSCsmay be used to investigate dis-
ease mechanisms that may not be exposed in non-neuronal cell types.
As iPSC technology and protocols for directed differentiation continues
to develop, hiPSC models have the potential to greatly reduce the time
and costs associated with clinical trials of drug discovery.
Limitations of iPSCs
Technical limitations
Despite the tremendous potential of hiPSCs, a number of technical
limitations currently restrict hiPSC-based studies. These limitations
relate primarily to several forms of variability arising fromdifferences be-
tween hiPSC-neurons derived from a single patient, from independent
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lines derived from different patients. In order to address these con-
straints, large experiments consisting of multiple neuronal differentia-
tions from multiple independent hiPSC lines from multiple patients
would have to be performed. Due to the time constraints and costs in-
volved with these large experiments, most hiPSC studies have used a
minimal number of cell lines and neuronal differentiations for proof-of-
principle experiments.
Most established methods of directed differentiation result in
heterogeneous populations of differentiated cells. These impure popula-
tions typically consist of different subtypes of neurons, as well as non-
neuronal cell types. This heterogeneity leads to differences between
individual hiPSC neurons derived from a single patient, or neuron-to-
neuron variability. Some studies have addressed this issue by using
ﬂuorescent-activated cell sorting (FACS) to purify speciﬁc neuronal sub-
types. To do this, hiPSC-derived neuronal culturesmay be transfected or
transduced with a plasmid or a virus encoding a ﬂuorescent protein
under the control of a subtype-speciﬁc promoter, such that only the spe-
ciﬁc neuronal subtypes will express the ﬂuorescent protein, which can
subsequently be sorted from the heterogeneous population. This has
been used to identify small molecules that improve survival of hiPSC
motor neurons from ALS patients (Yang et al., 2013). Although FACS
generates highly pure cultures and minimises neuron-to-neuron
variability, this method carries a risk of contamination and also results
in a lower yield of cells.
In addition to this, hiPSC clones derived from a single patient
are known to exhibit differences genetically and in differentiation
propensities (Hu et al., 2010). Genetic variability may arise from the
reprogramming process, due to differences in the number of viral inte-
grations or spontaneousmutations (Gore et al., 2011).While the former
issue may be addressed by non-integrating viral vectors or the use of
small molecules, spontaneous mutations occur naturally and are an
inherent variability in hiPSC-based studies. Indeed, a major limitation
of hiPSC research stems from the accumulation of mutations in rapidly
cycling cultured cells, such as hiPSCs and human ESCs (Baker et al.,
2007; Mayshar et al., 2010). Duplication of chromosomal regions has
been reported to occur in a proportion of the hiPSC and human ESC
lines analysed (Taapken et al., 2011). Biased gene expression associated
with such chromosomal aberrations has also been observed in some of
the hiPSC lines analysed, as a result of culture adaptation, although bi-
ased gene expression was also found at an early passage of one hiPSC
line (Mayshar et al., 2010). To work around these limitations, studies
may be performed on early passage hiPSC clones that have passed rigor-
ous quality controls, including morphological, gene expression and
karyotype analyses, tests for contaminants, and with RNA and DNA
methylation proﬁling.
Another form of variability derives from differences between hiPSC
lines derived from different patients, or inter-patient variability. For
instance, hiPSC lines have been shown to differentiate into neuronal
lineages with variability in differentiation efﬁciency and in electrophys-
iological properties (Hu et al., 2010). Inter-patient variability has also
been associated with donor identity and sex (Boulting et al., 2011).
Some studies have taken advantage of the recent development of ge-
nome editing technologies to circumvent such variability by generating
isogenic hiPSC lines. Much of these differences continue to reduce with
the development of pluripotent stem cell technology. The use of com-
mercially available cell culture media, substrates and reprogramming
kits has increased the quality and consistency of hiPSC cultures. The
development of protocols for the directed differentiation of hiPSCs has
led to better deﬁned culture conditions and more reliable neuronal
cultures.
Reproducibility
In addition to the intra- and inter-patient variability discussed
above, it is important to consider the reproducibility of hiPSC-basedstudies. Unlike studies involving the use of well-established cell lines,
the experimental design in iPSC-based studies is heavily debated. For
instance, it is not clear how many patients or iPSC lines should be in-
cluded in a study, nor is it clear whether data from different studies
can be compared, due to differences in the origin of the donor tissue,
reprogramming method or differentiation protocol.
It has been suggested that iPSCs retain a memory of the tissue from
which they are derived, which could affect their ability to differentiate
into certain cell lineages (Marchetto et al., 2009). Subtle differences in
global gene expression have been reported between iPSCs derived
from different somatic tissues from the same individual, and between
iPSCs derived the same individual, but reprogrammed by different
methods (Rouhani et al., 2014). Despite this, these differences are con-
siderably less than that observed for inter-individual transcriptional
variation in iPSCs (Rouhani et al., 2014). Therefore, it is likely that
cellular phenotypes between different iPSC lines are likely driven by dif-
ferent genetic backgrounds rather than donor tissue or reprogramming
method. Indeed, an examination ofmultiple iPSC lines derived from dif-
ferent individuals showed greater inter-individual than intra-individual
differences in expression of motor neuron markers (Boulting et al.,
2011). These ﬁndings suggest that iPSC-based studies should focus on
working with iPSC lines from different donors rather than multiple
lines derived from the same individual (Rouhani et al., 2014).
The issue regarding the use of differentiation protocols remains
unclear. Similar differentiation efﬁciencies have been obtained by inde-
pendent laboratories using the same standardised procedures (Boulting
et al., 2011), supporting the reproducibility of iPSC-based studies. How-
ever, many iPSC-based studies use alternative differentiation protocols,
which make it difﬁcult to interpret ﬁndings from different studies. Two
independent studies using different differentiation protocols have re-
ported an identical biochemical phenotype in iPSC-derived neurons
with the same genotype (Bilican et al., 2012; Egawa et al., 2012). Alter-
natively, two independent studies using different differentiation proto-
cols recently reported dissimilar rates of cell death in iPSC-derived
neurons with the same genotype (Chen et al., 2014; Kiskinis et al.,
2014). As mentioned previously, the development of simpler and
more affordable methods for hiPSC culture and differentiation should
enable the generation of robust, large-scale neuronal cultures to enable
reproducibility of hiPSC studies.
Time
A notable constraint in the use of iPSCs for studies of basic and
disease mechanisms regards the time frame of in vitro experiments
and the time required for the onset of psychiatric and neurological
diseases. It has been shown that the gene expression proﬁles of hiPSC-
derived neural progenitors shared highly similar gene expression
proﬁles with brain tissue at 8–16 weeks post conception, whereas
hiPSC-derived neurons shared the most similarity gene expression
proﬁles with brain tissue at 8–24 weeks post conception (Brennand
et al., 2015). These ﬁndings present a challenge for the study of adult-
onset neurological conditions. Indeed, most reports of adult-onset
disorders or late-onset neurodegenerative conditions have not been
able to model the loss of neurons that is typical in human disease.
Rather, these studies have identiﬁed susceptibility to particular cellular
stressors (Bilican et al., 2012; Israel et al., 2012), instead of explicit
degeneration.
A recent study showed that it may be possible to circumvent the
fetal identity of iPSC-derived neurons. Progerin is a truncated form of
a nuclear membrane protein and is involved in Hutchinson–Gilford
progeria syndrome, a genetic disorder characterised by premature age-
ing. Miller et al. (2013) found that the expression of progerin protein
leads to the induction of ageing-related events in hiPSCs. Importantly,
the expression of progerin in hiPSCs from Parkinson's disease patients
enabled the emergence of disease-relevant phenotypes (Brennand,
2013; Miller et al., 2013). Although the expression of progerin appears
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reﬂect all aspects of ageing and alternative approaches need to be devel-
oped to address the issue of age identity.
Modelling the effects of estrogens in human stem cells and iPSCs
Estrogens and estrogen receptors in human stem cells
To date there have been a select few studies that have investigated
the effects of estrogens in human neural stem cells (hNSCs) or neural
progenitor cells (hNPCs). In this review we deﬁne NSCs and NPCs as
any self-renewing neural cell capable of differentiation into neurons,
astrocytes and/or oligodendrocytes, and will use these terms inter-
changeably. The study by Hong et al. (2004), was one of the ﬁrst to
investigate the expression of ERs and other steroid receptors in
human embryonic stem cells (hESCs), multipotent cells capable of
differentiating into various cell types from the 3 germ layers (Hong
et al., 2004). This study demonstrated that mRNA for ERα, ERβ, gluco-
corticoid receptor (GR), and progesterone receptor (PR) were present
in hESCs, but did not investigate ER expression beyond this stage
(Hong et al., 2004). However, it was not until Kishi et al. (2005) that
the presence of these receptors and the effect of 17β-estradiol on
hNSC differentiation were demonstrated. In this study, both ERα and
ERβwere found to be expressed in hNSCs derived from fetal mesence-
phalic tissue. Differentiation of these midbrain hNSCs further gave rise
to a population of tyrosine hydroxlase positive neurons in which a sim-
ilar proportion of these neurons expressed ERα and ERβ as determined
by immunoﬂuorescence (Kishi et al., 2005). Interestingly, 17β-estradiol
increased the number of tyrosine hydroxlase positive neurons following
differentiation in vitro, in a dose-dependent manner, and moreover,
in vivo after transplantation intomouse brains. Thus, these data indicat-
ed that 17β-estradiol could inﬂuence the differentiation of mesence-
phalic hNSC into dopamine neurons in vitro and in vivo. It should be
noted that the effect of 17β-estradiol on the number of grafted hNSCs
in vivo could be due to an increase in cell survival following transplan-
tation (Kishi et al., 2005).
In addition to regulating differentiation, 17β-estradiol has also
been shown to inﬂuence the proliferation of hNPCs. Using hNPCs de-
rived from fetal cortex, Wang et al. (2008) showed that treatment
with 17β-estradiol increased hNSC proliferation in a dose- and time-
dependent manner. Assessment of ER expression revealed a predomi-
nate expression of ERβ; ERα expressed was reported to be barely
detectable (Wang et al., 2008). Using ER selective agonists, the authors
further demonstrated that the ERβ agonist, DPN, but not the ERα
agonist, PPT, was capable of increasing hNPC proliferation. Treatment
with 17β-estradiol and DPN, but not PPT, also resulted in an increase
in phosphorylation of the MAP kinases, ERK1/2. Critically, 17β-
estradiol and DPN induced cell proliferation was blocked in the pres-
ence of the MEK kinase (a direct regulator of ERK1/2 phosphorylation)
inhibitor, U0126 (Wang et al., 2008). Therefore, the data from this
study indicates that ERβ is the predominate ER in cortical hNPCs, and
mediates hNPC proliferation via a MEK/ERK1/2-dependent pathway.
Several studies have also investigated ER expression, and the func-
tion of 17β-estradiol in human neurons derived from either fetal tissue
or hESCs. Fried et al. (2004) demonstrated that ERβ was highly
expressed in primary cultures of neurons and glial cells generated
from human embryo cortex and spinal cord. Furthermore, treatment
with 17β-estradiol increased the expression of ERβ (Fried et al., 2004).
While this study suggested that young developing human neurons do
express ERβ, it was not clear whether ERα is also expressed in fetal
neurons. More recently, Zhang et al. (2010) have shown that ERβ, but
not ERα is expressed in neurons differentiated from the hESC lines, H7
and H9. In order to determine whether 17β-estradiol, or activation of
either ERα or ERβ could inﬂuence cell function, the authors examined
Ca2+ oscillations (Zhang et al., 2010). In both H7 and H9-derived neu-
rons, 17β-estradiol rapidly (within minutes) increased the frequency,amplitude and synchrony of Ca2+ oscillations. Additionally, treatment
of these neurons with 3 independent ERβ agonists, DPN, WAY-202041
or MF101, also increase the frequency, amplitude and synchrony of
Ca2+ oscillations within a few minutes (Zhang et al., 2010). However,
the ERα agonist, PPT, had no effect on Ca2+ oscillations, mirroring the
apparent lack of ERα expression in H7 or H9-derived neurons. Similar
results were also obtained in neurons derived from a mouse ESC line.
Taken together, the data from these studies suggest that ERβ can not
only regulate hNPC proliferation, but is also able to regulate Ca2+ signal-
ling in human neurons derived from an hESC source, and thus may play
a predominate role during neuronal development.
These studies are amongst the ﬁrst to study the effects of 17β-
estradiol on cellular physiology in human neural tissue. However, a
number of limitations are associated with hNSC and hESCs. Firstly, a
considerable amount of variation is seen between different cell lines
(Adewumi et al., 2007), making it difﬁcult to generalise and reproduce
results across different lines. In addition, NSCs only differentiate into
speciﬁc neural lineage, determined by which brain region they were a
derived from. Critically, hNSCs and hESCs do not offer the ability to reca-
pitulate the ploygenic background associated with speciﬁc neurological
diseases. Nevertheless, these studies do offer us important insights into
the actions of estrogens in human neurons. For example, a number of
animal studies, both in vivo and in vitro, have reported similar effects
of 17β-estradiol to that observed in hNSCs and hESCs. Treatment of
rat glioma and mouse hippocampal neurons with 17β-estradiol has
been shown to improve cell viability (Behl et al., 1995; Bishop and
Simpkins, 1994), and administration of 17β-estradiol was shown to
reduce mortality from focal ischemia in rats (Zhang et al., 1998). In
addition, increases in dendritic spine density following exposure to
estrogens have been observed in primary hippocampal neurons
(Murphy and Segal, 1996), cortical neurons (Srivastava et al., 2008)
and in cortical and hippocampal neurons of adult rats (Inagaki et al.,
2012; Woolley and McEwen, 1992). Moreover, Zhang et al. (2010)
directly compared the effect of 17β-estradiol on Ca2+ oscillations in
neurons derived from hESCs and mouse ESCs, and reported similar in-
creases in Ca2+ signalling and activation of kinase pathways in neurons
fromhuman ormouse ESCs suggesting a commonmechanism of action.
Thus, these ﬁndings provide conﬁdence that in vitro experiments using
hNSC/ESCs or hiPSC neuronswould be able tomodel the actions of 17β-
estradiol within the human brain.
Characterising the effects of 17β-estradiol in hiPSCs
To our knowledge, no study has thus far investigatedwhether estro-
gens are functionally active in neurons derived from hiPSCs. To this end
we established an iPSC line fromhair keratinocytes of a healthymale in-
dividual. Hair keratinocytes were reprogrammed using nonintegrating
approach; cells were transduced with Sendai virus expressing OCT4,
SOX2, KLF4 and C-MYC (kind gift of M. Nakanishi, AIST Japan)
(Nishimura et al., 2011; Takahashi et al., 2007a) (also see Cocks et al.
(2014)). Detailed quality control analyses of the hiPSC line was
performed aspreviously described (Cocks et al., 2014). In order to inves-
tigate the effects of 17β-estradiol in neurons differentiated from this
hiPSC line, we utilized a neuralization protocol that has previously
been used to generate forebrain/cortical neurons (Cocks et al., 2014;
Shi et al., 2012). Brieﬂy, hiPSCs were differentiated in a monolayer,
in the presence of SMAD inhibitors, Dorsomorphin, and SB431542
(Fig. 3A). This resulted in the generation of a relatively homogenous
population of neuroepithelial cells, which were positive for the NSC
markers, nestin, an intermediate ﬁlament protein, and SOX2, a marker
of self-renewal, or pluripotency (Fig. 3B) (Chambers et al., 2009; Cocks
et al., 2014; Shi et al., 2012; Yoon et al., 2014). Subsequent passaging
of this population of neuroepithelial cells resulted in the generation of
cortical neural rosettes (Fig. 3C) (Chambers et al., 2009; Cocks et al.,
2014; Shi et al., 2012; Yoon et al., 2014). The apical lumen of neural
rosettes showed robust expression of the adhesion marker, ZO-1,
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(Fig. 3C) (Cocks et al., 2014; Shi et al., 2012). Terminal differentiation
of hNPCs into neurons was achieved by the addition of the NOTCH
inhibitor DAPT for 5 days (Cocks et al., 2014). This gave rise to the gen-
eration of a large number of TBR1-positive neurons, a marker of layer V
cortical neurons (Espuny-Camacho et al., 2013; Shi et al., 2012), indicat-
ing that themajority of cells had differentiated into excitatory forebrain/
cortical projection neurons (Fig. 3D).
While the forebrain consists of both glutamatergic projection
neurons and GABAergic interneurons, previous studies have shown
that forebrain excitatory glutamatergic neurons are generated by corti-
cal progenitor cells, whereas forebrain GABAergic interneurons origi-
nate from the ganglionic eminence and migrate into the cerebral
cortex (Sussel et al., 1999). Several recent studies have shown that the
differentiation of hiPSCs into these two neuronal subtypes requires dif-
ferent inductive signals. Shi et al. (2012) reported that the combination
of retinoid signalling and SMAD inhibition led to the induction of
neuroepithelia with apico-basal polarity unique to cortical progenitors,
which subsequently differentiated into cortical projection neurons. In
contrast, the differentiation of GABAergic interneurons requires the
ventralisation of primitive neuroepithelia into medial gangolionic
eminence-like progenitors, which subsequently differentiate intoMAP2 + DAPI
A
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C
Control 17 -estradiol
D
Fig. 4. Differentiated hiPSC-neurons display features of pyramidal neurons. (A) Representa
DAPI nuclear stain (blue). hiPSC-neurons display the development of neuronal morphologywit
frommain dendrites are also evident, demonstrating a limited level of arborisation. (B) Express
play a polarised morphology; an axonal process can be identiﬁed, and a single, primary dendri
dendrite of day 45 hiPSC-neurons expressing eGFP and co-stained for the pre-synaptic marker
immature dendritic spines co-localize with synapsin1 (yellow arrowheads) suggesting that the
results in an increase in dendritic branching. N = 18–23 cells per condition, from 3 experimenvarious GABAergic interneuron subtypes (Liu et al., 2013a). In our lab,
we have focused on the generation of glutamatergic projection neurons,
which represents the majority of neurons in the cerebral cortex. How-
ever, the study of GABAergic interneurons, and the co-culture of these
two neuronal subtypes, is warranted to better recapitulate cortical
development.
An important characteristic of cortical glutamatergic neurons is their
ability to generate unipolar pyramidal neuronal morphology; interneu-
rons developmultipolarmorphologies (Dotti et al., 1988; Gaspard et al.,
2008; Markram et al., 2004). Previously it has been shown that cortical
neurons differentiated from hESCs also generate unipolar pyramidal
neuronal morphologies (Gaspard et al., 2008). After 35 days of differen-
tiation, we found that the majority of MAP2-positive cells displayed a
unipolarmorphology thatwould be associatedwith a young developing
neuron (Fig. 4A). In order to examine themorphology of neurons differ-
entiated for longer periods of time, we transfected cells with eGFP
to outline cell morphology. By day 45 hiPSC neurons had adopted a
polarised neuronal morphology; Fig. 4B shows a representative image
of an eGFP expressing hiPSC-neuron that has formed a single primary
dendrite with secondary and tertiary dendritic arborisations, and the
characteristic speciﬁcation of an axonal process (Fig. 4B). Thismorphol-
ogy is indicative of a young, yet maturing pyramidal neuron. DuringSoma
AxonGFP
B
Dendrite
GFP + Synapsin1
Day 45 hiPSC-neuron
**
tive image of hiPSC-neurons differentiated for 35 days and stained for MAP2 (green) with
h dendrites clearly present. Additional smaller processes protruding from the cell soma or
ion of eGFP in 45 hiPSC-neurons differentiated for 45 days. By this age, hiPSC-neurons dis-
te with secondary and tertiary branches is also evident. (C) High magniﬁcation images of
. This reveals the presence of ﬁlipodia and immature (thin) dendritic spines. Occasionally,
se cells are undergoing synaptogenesis. (D) Treatmentwith 17β-estradiol (10 nM) for 24 h
ts. **p b 0.01, Student t-test. Scale bar, 20 μm (A + B), 5 μm (C), 10 μm (D).
238 C. Shum et al. / Hormones and Behavior 74 (2015) 228–242early postnatal development, synaptic dendritic protrusionsﬁrst appear
as long, thin, highlymotile structures known as ﬁlopodia, which can ini-
tiate synaptic contacts with nearby axons (Yoshihara et al., 2009; Ziv
and Smith, 1996). This initial contact between pre- and post-synaptic
sides is a key step in synaptogenesis. The subsequent maturation and
stabilisation of synapses are thought to involve ﬁlipodia transforming
into highly specialised dendritic protrusions known as dendritic spines
(Yoshihara et al., 2009; Ziv and Smith, 1996). Consistent with this
hiPSC-neurons grown for 45 days also displayed dendritic protrusions
along the dendritic shaft (Fig. 4C). Interestingly, a number of these den-
dritic protrusions co-localizedwith the pre-synaptic marker, synapsin1,
suggesting that these protrusion maybe very immature dendritic spine
involved in synaptogenesis (Fig. 4C).
Following the establishment of hiPSC neurons with a forebrain/
cortical lineage, we next asked whether these cells could respond to
the application of 17β-estradiol. Thus, we took advantage of the power-
ful effect that 17β-estradiol has on regulating neuronal morphology
during development (Arevalo et al., 2012; Srivastava and Evans, 2013;
Srivastava et al., 2013). To this end, we treated day 34 hiPSC-neurons
with either 17β-estradiol (10 nM) for 24 h. Examination of neuronal
morphology of MAP2-positive day 35 neurons revealed that 17β-
estradiol treatment increased the number of dendritic branches
(Fig. 4D), an observation consistent with previous studies (Arevalo
et al., 2012).While this indicates that hiPSC-neurons are indeed respon-
sive to 17β-estradiol, it also demonstrates thatmale humanneurons are
responsive to estrogenic signalling. These preliminary observations
provide evidence that 17β-estradiol is capable of inducing structural
changes in neurons differentiated from hiPSCs, derived from a healthy
male individual. It will be critical in the future to conﬁrm that these
neurons are indeed functional, and to investigate the expression of
ERs in these cells. Nevertheless, these data indicate that hiPSCs are a
suitable platform fromwhich to investigate the role of estrogens during
neuronal development and even in disease.
Conclusions
In this reviewwe have attempted to highlight the recent advances in
the ﬁeld of stem cell research and in particular iPSCs. It is clear that this
ﬁeld of study rapidly developing andmoreover, that this approach does
hold much potential for investigating the basic mechanisms of neural
developments (Gaspard and Vanderhaeghen, 2011). Critically, this
approach is emerging as a key tool for further developing our under-
standing of neurodevelopmental and degenerative disease by revealing
novel insight into disease pathophysiology or the screening of potential
therapeutic compounds (Brennand et al., 2012; Cocks et al., 2014;
Dolmetsch and Geschwind, 2011; Durak and Tsai, 2014; Gaspard and
Vanderhaeghen, 2011; Yu et al., 2013). A major advantage of hiPSCs
over hNSCs or hESCs, is that they can be generated using readily acces-
sible tissue from individuals of any age and they can be combined with
methods of directed differentiation to enable accessibility to multiple
different neural cell types. Human NSCs and ESC are derived from fetal
tissue, and thus are much harder to access. It is also unclear how
much variability there are between hNSCs and hESCs, and there is
considerable heterogeneity in their ability to differentiate into neural
tissue (Adewumi et al., 2007). Moreover, neurons generated from NSC
or ESCs are fate restricted, that is they are only capable of generating
neural cells of a speciﬁc lineage (Adewumi et al., 2007; Gaspard and
Vanderhaeghen, 2011). Critically, generation of iPSCs from patients
diagnosed with speciﬁc diseases, means that it is possible to model
the disorder using neurons that faithfully recapitulate the cellular
environment of a disease state. However, iPSC technology is still in its
infancy with several limitations, although this aspect of the technology
is currently under being research by many laboratories. Moreover, this
in vitro technology is unlikely to replace animal models of disease, but
as has already been shown, provides a complementary tool, and an
entry point in identifying novel pathogenic mechanisms that cansubsequently be modelled in vivo using animal models. Despite these
caveats and limitations, several advances in our understanding of
neurological disorders have already been made using patient-derived
hiPSCs (Brennand et al., 2012; Durak and Tsai, 2014; Gaspard and
Vanderhaeghen, 2011).
As stated above, estrogens have a powerful inﬂuence over cognition.
Moreover, estrogens or estrogen-based therapies continue to be
suggested as potential therapeutic strategies, despite well described
side effects.We propose that one route to understanding the full poten-
tial of such strategies and in order to develop more effective and safer
estrogen-based therapies, is to utilize the ability of hiPSCs to provide a
native human cellular environment. This enables us to investigate the
actions of estrogens at a molecular level in native human neurons.
Moreover, it would allow for a greater understanding of how estrogens
may affect cellular processes in a physiologically relevant cellularmodel
carrying the precise genetic variants that contributed to neurological
conditions. As our preliminary data indicates that hiPSCs are indeed
responsive to 17β-estradiol, we feel that this is an achievable idea, al-
though, this work needs to be carefully replicated and considered in
light of the limitations as an in vitro system. Patient-derived hiPSCs
that recapitulate the complex genetics associated with many disorders
of the brain, have the potential to ﬁll a critical gap in determining both
how estrogens, or altered levels of estrogens, may contribute to patho-
genetic mechanism, and moreover, provide platform from which to
develop more effective and safer estrogen-based therapeutics, even in
a sex-speciﬁc manner.
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